A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.
Metastatic Melanoma
DRUG: Obatoclax Mesylate|DRUG: Temozolomide
Determine the recommended Phase II dose of GMX1777 in combination with temozolomide, 2 years|Learn more about the side effects of taking GMX1777 in combination with temozolomide, Within the first 4 weeks|Determine the disease response to treatment with GMX1777 in combination with temozolomide, Within the first 8 weeks
Learn more about how the body processes GMX1777, Within the fisrt 30 days
GMX1777 will be administered as 3-Hour Infusions in Combination with Temozolomide taken orally for the treatment of Metastatic Melanoma. GMX1777 infusion will be given on either day 1, days 1 and 3, or days 1,3, and 5 every 4 weeks. Temozolomide will be administered on 5 consecutive days every 4 weeks. No investigational or commercial agents or therapies other than those described may be administered with the intent to treat the patient's malignancy.